Predictive Value of PIIINP Urinary for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation (MUCO-IRC)

Nantes University Hospital (NUH)

Status: Terminated

Conditions: Renal Failure; Lung Transplantation; Cystic Fibrosis

Treatments: Biological: Urinary levels of PIIINP as a marker of changes in renal function

Study type: Interventional

Funder types: Other

Identifiers

NCT01572194

RC11_0215

Details and patient eligibility

About

Chronic renal failure is a serious complication of lung transplantation especially in patients with cystic fibrosis. Their medical history prior to the Lung Transplantation has already exposed to kidney damage. Post-lung transplantation, these patients are subjected to renal toxicity anticalcineurins they receive large doses.

The measurement of renal function of patients by formula to estimate GFR in routine use is unreliable and other markers seem indispensable.

The purpose of this study is to evaluate two markers, PIIINP (Procollagen III aminoterminal peptide N), whose urinary levels was correlated to the intensity of fibrosis in different types of kidney disease.

Enrollment: 45 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Bearer of lung transplantation (single or double lung, with or without associated cardiac transplantation)
• Suffering from cystic fibrosis
• Aged 18 and over
• With at least 6 months of transplantation
• Having a glomerular filtration rate measured by technical radionuclide > 30 ml / min
• Having given written consent to the study Patients meeting these criteria will enter in the "organic" in the study (determination of PIIINP urinary)

Exclusion criteria

• Lung transplantation for a condition other than cystic fibrosis
• Patient refused follow-up
• Patients with advanced liver disease (conditions that interfere with the assay of PIIINP)
• Minor
• Pregnant women,
• Major Trust, benefiting from a regime of legal protection (guardianship, trusteeship, safeguarding justice.
• Patient unable to grant informed consent.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)